MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$144.67
−2.49%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$147.02
From 52W high−7.53%
Volume8.86M
Market cap$356.93B
P/E (TTM)147.6x
P/S (TTM)5.3x
Div yield2.35%
Key dataNov 3, 2026
Open
$147.02
From 52W high
−7.53%
Volume
8.86M
Market cap
$356.93B
ValuationView details →
P/E (Fwd)
17.0x
EV/EBITDA
—
P/E (TTM)
147.6x
RSI (14)
49.9
MomentumView details →
1D Return
−2.49%
YTD Return
+38.04%
SummaryUpdated Sep 1, 2026
Merck & Co., Inc. (NYSE:MRK) is one of the world's largest pharmaceutical companies, founded in 1891 and headquartered in Kenilworth, New Jersey. Originally established as the American subsidiary of the German chemical company E. Merck, the company became independent during World War I and has since evolved into a global healthcare leader. Today, Merck operates as a diversified healthcare company serving patients worldwide through two primary business segments: pharmaceuticals for human health and animal health products. The company has built its reputation on developing breakthrough medicines and vaccines that address some of the most challenging diseases facing humanity.
Similar companies
Latest newsMore news →
The US Food and Drug Administration granted Merck & Co., Inc. emergency use authorization for a treatment for screwworm in dogs.17h agoMerck & Co., Inc. announced the initiation of the Phase 3 ENHANCE-3 trial evaluating Ohtuvayre (ensifentrine) to prevent COPD exacerbations in adults receiving standard of care, with recruitment underway.1d ago